{"id":"abl001","safety":{"commonSideEffects":[{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4208229","moleculeType":"Small molecule","molecularWeight":"449.85"},"_fixedAt":"2026-03-30T18:28:53.939579","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABL001 targets the BCR-ABL tyrosine kinase through an allosteric mechanism, binding to a regulatory site rather than competing for ATP binding. This approach enables activity against BCR-ABL variants that have developed resistance to ATP-competitive inhibitors like imatinib and dasatinib. The allosteric binding preserves normal ABL kinase regulation while selectively inhibiting the oncogenic BCR-ABL fusion protein.","oneSentence":"ABL001 is an allosteric inhibitor of BCR-ABL that binds to a pocket distinct from the ATP-binding site, allowing it to overcome certain resistance mutations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:35.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML) with BCR-ABL mutations resistant to standard tyrosine kinase inhibitors"}]},"_fixedFields":["pubmed(26)"],"trialDetails":[{"nctId":"NCT07250087","phase":"PHASE1","title":"Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-01-21","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT07354074","phase":"PHASE2","title":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-04","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive","enrollment":50},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT04948333","phase":"PHASE3","title":"Asciminib Treatment Optimization in ≥ 3rd Line CML-CP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-13","conditions":"Chronic Myelogenous Leukemia","enrollment":199},{"nctId":"NCT07039760","phase":"EARLY_PHASE1","title":"Asciminib With or Without Sildenafil for Brain Tumors","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-04-30","conditions":"Brain Tumor","enrollment":12},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT04877522","phase":"PHASE4","title":"Asciminib Roll-over Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-30","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":347},{"nctId":"NCT06773936","phase":"PHASE2","title":"Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","status":"ENROLLING_BY_INVITATION","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-15","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia","enrollment":55},{"nctId":"NCT06236724","phase":"PHASE2","title":"Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-31","conditions":"Chronic Myeloid Leukemia","enrollment":50},{"nctId":"NCT04216563","phase":"PHASE2","title":"ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia","enrollment":7},{"nctId":"NCT06629584","phase":"PHASE2","title":"Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-14","conditions":"Malignant Solid Tumors","enrollment":40},{"nctId":"NCT05456191","phase":"PHASE3","title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-21","conditions":"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia","enrollment":568},{"nctId":"NCT06092879","phase":"","title":"Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-06","conditions":"Chronic Myeloid Leukemia","enrollment":201},{"nctId":"NCT07387926","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-26","conditions":"Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT07375355","phase":"","title":"Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-02-27","conditions":"Chronic Myeloid Leukemia in Chronic Phase","enrollment":200},{"nctId":"NCT06308588","phase":"PHASE1, PHASE2","title":"Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-05","conditions":"Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia","enrollment":40},{"nctId":"NCT03874858","phase":"PHASE2","title":"A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-22","conditions":"Chronic Myeloid Leukemia","enrollment":124},{"nctId":"NCT06684964","phase":"","title":"RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-03-24","conditions":"Chronic Myelogenous Leukemia in Chronic Phase","enrollment":40},{"nctId":"NCT07136428","phase":"PHASE1, PHASE2","title":"Asciminib in HER2+ Breast Cancer Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-02","conditions":"HER2+ Metastatic Breast Cancer","enrollment":42},{"nctId":"NCT04360005","phase":"","title":"Managed Access Programs for ABL001, Asciminib","status":"AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Chronic Myeloid Leukemia in Chronic Phase","enrollment":""},{"nctId":"NCT03578367","phase":"PHASE2","title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-22","conditions":"CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic","enrollment":104},{"nctId":"NCT03595917","phase":"PHASE1","title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","status":"RECRUITING","sponsor":"Marlise Luskin, MD","startDate":"2018-07-24","conditions":"B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL","enrollment":40},{"nctId":"NCT06427811","phase":"PHASE4","title":"Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-28","conditions":"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase","enrollment":85},{"nctId":"NCT04666259","phase":"PHASE3","title":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-25","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":56},{"nctId":"NCT05384587","phase":"PHASE2","title":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-11","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":34},{"nctId":"NCT07188428","phase":"","title":"Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-27","conditions":"Leukemia, Chronic Myeloid","enrollment":2298},{"nctId":"NCT06514534","phase":"PHASE2","title":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-18","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":20},{"nctId":"NCT04925479","phase":"PHASE1, PHASE2","title":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-27","conditions":"Myeloid Leukemia, Philadelphia Positive","enrollment":44},{"nctId":"NCT04838041","phase":"PHASE2","title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-11","conditions":"Chronic Phase Chronic Myelogenous Leukemia","enrollment":51},{"nctId":"NCT07091019","phase":"","title":"A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-15","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":1000},{"nctId":"NCT06409936","phase":"PHASE2","title":"PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML","status":"RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2025-06-26","conditions":"CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive","enrollment":160},{"nctId":"NCT07040982","phase":"PHASE1","title":"Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-01","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":30},{"nctId":"NCT05413915","phase":"PHASE3","title":"Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarit Assouline","startDate":"2023-11-01","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia in Remission","enrollment":164},{"nctId":"NCT04795427","phase":"PHASE2","title":"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-06","conditions":"Leukemia, Chronic Myelogenous","enrollment":84},{"nctId":"NCT03106779","phase":"PHASE3","title":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-10-26","conditions":"Chronic Myelogenous Leukemia","enrollment":233},{"nctId":"NCT03906292","phase":"PHASE2","title":"Frontline Asciminib Combination in Chronic Phase CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jena","startDate":"2019-08-19","conditions":"Chronic Myeloid Leukemia","enrollment":125},{"nctId":"NCT04492033","phase":"PHASE1, PHASE2","title":"A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients","status":"TERMINATED","sponsor":"Handok Inc.","startDate":"2020-06-22","conditions":"P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer","enrollment":41},{"nctId":"NCT05943522","phase":"","title":"Asciminib RMP Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-19","conditions":"Chronic Myeloid Leukemia","enrollment":100},{"nctId":"NCT06516029","phase":"","title":"Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib","status":"COMPLETED","sponsor":"Novartis","startDate":"2023-04-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":111},{"nctId":"NCT06368414","phase":"PHASE2","title":"A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Korean Society of Hematology","startDate":"2024-09-01","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":69},{"nctId":"NCT05421091","phase":"","title":"Special Drug Use-results Surveillance of Scemblix Tablets","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-04","conditions":"Chronic Myeloid Leukemia","enrollment":550},{"nctId":"NCT02081378","phase":"PHASE1","title":"A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04-24","conditions":"Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","enrollment":326},{"nctId":"NCT06211153","phase":"","title":"Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-31","conditions":"Chronic Myeloid Leukemia With T315I Mutation","enrollment":31},{"nctId":"NCT06148493","phase":"","title":"Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-09-20","conditions":"Chronic Myeloid Leukemia","enrollment":425},{"nctId":"NCT03605277","phase":"PHASE1","title":"Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-16","conditions":"Renal Impairment","enrollment":14},{"nctId":"NCT03292783","phase":"PHASE1","title":"This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001","status":"COMPLETED","sponsor":"ABL Bio, Inc.","startDate":"2017-09-18","conditions":"Advanced Solid Tumors","enrollment":45},{"nctId":"NCT02857868","phase":"PHASE1","title":"A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-05-03","conditions":"Hepatic Impairment","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"recentPublications":[{"date":"2025 Jul 25","pmid":"40709730","title":"Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives.","journal":"Journal of chemotherapy (Florence, Italy)"},{"date":"2006","pmid":"40127374","title":"Asciminib.","journal":""},{"date":"2024 Dec","pmid":"39375952","title":"Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.","journal":"Cancer science"},{"date":"2024 Aug","pmid":"38906962","title":"Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells.","journal":"Leukemia"},{"date":"2022","pmid":"36263131","title":"The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants.","journal":"Frontiers in pharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABL001","genericName":"ABL001","companyName":"Marlise Luskin, MD","companyId":"marlise-luskin-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABL001 is an allosteric inhibitor of BCR-ABL that binds to a pocket distinct from the ATP-binding site, allowing it to overcome certain resistance mutations. Used for Chronic myeloid leukemia (CML) with BCR-ABL mutations resistant to standard tyrosine kinase inhibitors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}